Select your Market
Financial results of Q2 2023
Updated forecast for fiscal 2023
|
Q2 2023 (in € billion) | Change (in %, compared to Q2 2022) | Organic growth (in %, compared to Q2 2022) |
|---|---|---|---|
Group net sales | 5.3 | -4.8 | -1.1 |
EBITDA pre | 1.6 | ‑12.8 | ‑7.0 |
Life Science sales | 2.4 | -11.1 | -8.7 |
Healthcare sales | 2.0 | 6.5 | 11.9 |
Electronics sales | 0.9 | ‑9.7 | ‑6.3 |
For us, 2023 remains a transition year. In the second quarter, our Healthcare business once again proved to be a growth driver. We are building on the strengths of our diversified business model.
Our CFO Helene von Roeder comments on the Q2 2023 results.
Detailed information about the development of our business in the first half of 2023.
Downloads for the Media
Additional Downloads
Press Releases
In the second quarter of 2023, Merck KGaA, Darmstadt, Germany, leveraged its diversified portfolio with three business sectors to navigate a challenging market environment.
2023/08/03
Find previous Annual Reports, Corporate Governance Reports & Statements in our archive.
Read more
